Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial ...
Good evening and welcome to Doctors on Call back on our we're back on our 45th season at this time. I'm Dr. Ray Christensen, ...
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases. The University of Pittsburgh Medical Center (UPMC) faculty have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results